GORE® CARDIOFORM Septal Occluder Migraine Clinical Study
Terminated · Not applicable · NCT04100135
Conditions: Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale
At a glance
- Research payments reported, 2025
- $79,782
- U.S. investigators named
- 4
- Sites paid
- 5
- Planned or actual enrollment
- 7
About the trial
- Sponsor
- W.L.Gore & Associates
- Tested
- Actual device PFO closure (device), Thienopyridine (clopidogrel or prasugrel) (drug), Sham device PFO closure (device)
- Dates
- Started 2021-02-05; completion 2024-08-15
- Results posted
- Yes
Multi-center, prospective, randomized, placebo- and sham-controlled study to evaluate the GORE® CARDIOFORM Septal Occluder for migraine headache relief
From ClinicalTrials.gov, last updated 2026-06-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
W. L. Gore & Associates, Inc. reported $79,782 in research payments for this study in 2025 (15 payments).
Products named: Product in Development
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jeremy D. Asnes, MD Pediatric Cardiology · New Haven, CT
- Ignacio Inglessis-azuaje, MD Cardiology · Boston, MA
- Paul M. Grossman, MD Interventional Cardiology · Ann Arbor, MI
- Robert J. Sommer, M.D. Cardiology · New York, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Trustees of Columbia University in The City of New York $52,110
- Ronald Reagan UCLA Medical Center, CA $18,339
- University of Michigan Health System, MI $5,034
- Massachusetts General Hospital, MA $2,548
- Yale University $1,750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.